淋巴瘤
T细胞
免疫系统
T淋巴细胞
免疫学
癌症研究
混合淋巴细胞反应
生物
汽车T细胞治疗
免疫疗法
皮肤T细胞淋巴瘤
医学
细胞毒性T细胞
淋巴细胞亚群
移植
化学
计算生物学
细胞
PD-L1
淋巴细胞
作者
Andrew Philip Jallouk,Zhongqi Ge,Vivek Kaimal,Kristen Zhang,Elvin J. Lauron,Paul B. Robbins,Zachary J. Roberts,Emerie E Danson,Matthew D. Richard,Pragya Devashish,Sattva Swarup Neelapu,Pavan Bachireddy
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-09-25
卷期号:: OF1-OF18
标识
DOI:10.1158/2159-8290.cd-26-0248
摘要
Abstract Allogeneic chimeric antigen receptor (CAR) T cells could overcome limitations of autologous therapies but are limited by immune rejection. We evaluated 11 patients with large B-cell lymphoma treated with a single lot of cemacabtagene ansegedleucel (cema-cel), an allogeneic anti-CD19 CAR T product. Despite receiving identical infusion products (IP), patients exhibited heterogeneous cema-cel expansion and clinical outcomes. Our integrated analyses using longitudinal T-cell receptor (TCR) β sequencing, single-cell molecular profiling, and mixed lymphocyte reaction assays revealed that high frequencies of preexisting, recipient-derived alloreactive CD8+ T cells-mediated rapid CAR T rejection in nonexpanders. Furthermore, effector-like features, rather than stem/central memory programs, drove robust clonal CAR T expansion consistently across expanders. We confirmed similar expansion patterns in two independent cohorts treated with a separate lot of cema-cel or an allogeneic anti–B-cell maturation antigen (BCMA) CAR T product. These findings highlight distinct cell-extrinsic and cell-intrinsic mechanisms that influence allogeneic CAR T performance and provide insights to optimize donor selection, manufacturing, and product design. Significance: Clinical adoption of allogeneic CAR T-cell therapies has been limited by poor CAR T-cell expansion in some recipients. Using patient samples, we elucidated the cell-extrinsic and cell-intrinsic mechanisms governing allogeneic CAR T-cell rejection and expansion. Our findings provide actionable strategies to improve allogeneic CAR T-cell efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI